Delivery of IL-12 to the TME was linked to antitumor effects, correlating with the reprogramming of MDSCs, Tumor-associated dendritic cells (TADCs) and TAMs into antigen-presenting cells with CD8+ T cell activating potential [168,169]. This evidence concerns the gene CD8A and neoplasm.